FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar

The agency approved a higher concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Medscape Medical News

source https://www.medscape.com/viewarticle/990154?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost